A simulation model of the natural history of human breast cancer. by Koscielny, S. et al.
Br. J. Cancer (1985), 52, 515-524
A simulation model of the natural history of human breast
cancer
S. Koscielny', M. Tubiana2, & A.-J. Valleron'
IUnite de Recherches Biomathematiques et Biostatistiques INSERM U263 and Universite Paris 7 2, Place
Jussieu, 75251 Paris Cedex 05, and 2Institut Gustave Roussy, Rue Camille Desmoulins, 94800 Villejuif,
France.
Summary In order to assess the time at which the distant metastases were initiated, a model has been
developed to simulate the natural history of human breast cancer. The metastasis appearance curves were
fitted to those observed for tumours of various sizes among the 2648 patients treated at the Institut Gustave
Roussy from 1954 to 1972. The model assumes that metastases are initiated when the tumour reaches a
threshold volume (distribution of this volume was estimated in a previous article). Two patterns of growth
were considered: exponential and Gompertzian. Distributions of tumour and metastases doubling times are
fixed according to the literature. A relationship between tumour and metastasis doubling time is estimated.
Simulations were used to optimize metastases growth duration as a function of the metastasis doubling time.
The ages of the metastases at tumour diagnosis are calculated.
With exponential growth, it was necessary to introduce correlations to obtain a satisfactory fit of the
metastases appearance curves: between the tumour volume at diagnosis and the doubling time (RI = -0.3),
and between the tumour volume at metastasis initiation and the doubling time (R2=0.3). The growth
duration of the metastases before their detection was found to equal about 18 metastases doubling times at
detection and the mean ratio between the doubling time of a tumour and its metastases equal to 2.2.
With Gompertzian growth, it was impossible to adjust satisfactorily the proportions of metastases at
diagnosis as a function of the primary tumour volume. However, when we ignore this, the best fit was
obtained when the duration of metastases growth before detection was about the same as for exponential
growth.
With either growth pattern, the model predicts that the proportion of patients with metastases would be
reduced by -30% if the primary tumours were treated 12 months earlier. This prediction is consistent with
the results of the screening programs for breast cancer.
In a previous article we studied the relationship
between the size of the primary tumour at initial
treatment and the incidence of distant metastases
during the course of the disease. The data showed
that the primary tumour at the time of metastasis
initiation is, on the average, only slightly smaller
than at the time of tumour diagnosis (Koscielny et
al., 1984).
This conclusion conflicts with the predictions of
previous models of the natural history of breast
cancer. Igot & Legal (1968), and later Breuer (1976)
assumed that metastases grow exponentially from
the time of origin and they extrapolated metastases
growth curves backwards in order to determine
when the metastases contained one single cell.
Assuming identical growth rates for both primary
tumours and metastases, they concluded that
metastasis commences very early in the
development of the primary.
This divergence can be explained by the following
hypotheses: (a) the number of cells necessary for
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metastasis initiation is much greater than one. (b)
the metastasis growth rate is more rapid than the
primary tumour one. (c) tumour growth is not
exponential.
The model proposed in this paper was developed
in order to assess the time at which the distant
metastases were initiated, taking into account the
clinical data, particularly the relationship between
primary tumour size and the metastases appearance
curve.
Patients and methods
The population includes all patients with breast
epitheliomas treated at the Institut Gustave-Roussy
from 1954 to 1972. The only exclusions are: male
patients, patients having received their initial
treatment in another hospital, multifocal tumours,
and primary bilateral breast cancers. In this series,
none of the patients received adjuvant chemo-
therapy. We consider only the patients in whom the
clinical size of the primary tumour was assessed:
2,648 patients out of 2,918. We gave in a previous
paper (Koscielny et al., 1984) all pertinent infor-
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mation concerning these patients; in particular the
cumulative percentage of patients with distant
metastases with respect to the size of the tumour at
diagnosis. In the present study, the tumours were
grouped into three classes according to their
diameter (D) (class I: D.3.5cm; Class 2:
3.5<D<7.5cm; class 3: D>7.5cm).
The model
Scheme (Figure 1) Growth curves of primary
tumours and metastases are characterized by their
growth rate. The rate of growth is assessed by the
volume doubling time at detection (DT). The
doubling time is constant under the exponential
growth pattern and varies with the volume under
the Gompertzian.
Time
Figure 1 Schematic representation of the natural
history of breast cancer. It is assumed that metastases
are initiated (with an initial volume VOM) when the
primary tumour reaches the threshold volume (VOT).
The figure illustrates the course of the disease of a
patient whose primary tumour is detected at a volume
V1T, at a time at which its volume is larger than the
threshold volume. In this case, the metastasis becomes
detectable later when it reaches volume V1M (- 1 ml).
AGE means age of metastases at primary tumour
diagnosis, DELAY is the time interval between
primary tumour diagnosis and metastasis detection.
Two events occur during the history of a primary
tumour: (i) the initiation of distant metastases and
(ii) the diagnosis. The time of these two events is
different for every tumour. For a given tumour, the
volume of the primary tumour at which the first
metastasis is initiated is noted VOT. This volume is
the 'threshold volume' (Koscielny et al., 1984). If a
tumour is treated before it has reached this
threshold volume, metastases will not appear after
treatment. On the other hand, if the volume at
diagnosis (VIT) is greater than the threshold
volume (VOT) there will exist at least one
metastasis. This metastasis may be detectable at the
time of the primary tumour diagnosis, or may
appear later. The age of the metastasis at the time
of the primary tumour diagnosis is the duration
(Dl) of growth from the tumour volume at
metastasis initiation (VOT) up to the volume at
diagnosis (VIT). It is a function of the tumour
doubling time (DT). Data concerning the
distributions of the tumour volume at diagnosis
(VIT) and the doubling time (DT) are available.
The distribution of VOT can be estimated from the
relationship between the tumour volume at
diagnosis and the proportion of metastases at long
term (Koscielny et al., 1984).
The metastasis growth duration (D2) is the
duration of growth between its volume at initiation
(VOM) up to its volume at detection (VIM). For
simplicity, we suppose that VOM and V1M are the
same for all the metastases, under these conditions,
the metastases growth duration is a constant
number of metastases doubling times (see below,
Quantification of growth). Several articles have
reported values of doubling times which have been
measured for metastases as well as for primary
tumours, but the relationship between them is not
accurately known.
Using the above notation, the delay between the
primary tumour diagnosis and the appearance of
distant metastases is equal to D2-Dl. The
distribution of this delay is documented by the
cumulated metastases appearance curves.
Quantification of growth With the Gompertzian
growth pattern (see Appendix), the growth duration
(t) from an initial volume Vi to a volume Vt is
calculated as:
t=DT Ln{Ln(Vm/Vi)/Ln(Vm/Vt)}Ln(Vm/Vt)/Ln(2)
(1)
where Ln symbolises the Napierian logarithms, Vm
the maximum asymptotic volume, and DT the
doubling time when the volume is Vt.
The doubling time (DT°) can be expressed as a
function of the volume (V°):
DT° =DTLn(Vm/Vt)/Ln(Vm/V°) (2)
With the exponential growth pattern, t is equal to:
t=DTLn(Vt/Vi)/Ln(2). (3)A MODEL OF THE NATURAL HISTORY OF BREAST CANCER 517
The doubling time is constant all over the growth.
Therefore DT° =DT.
The exponential growth can be considered as a
particular case of the Gompertzian where Vm is
infinite.
The model parameters The distributions of all the
observational variables were taken to be lognormal.
Lognormality is consistent with data concerning the
doubling times (Spratt & Spratt, 1964; Charbit et
al., 1971; Steel, 1977), the metastases volumes at
detection (Spratt & Spratt, 1964) and also with the
data from our population concerning the primary
tumour volumes. The characteristics of these distri-
butions are reported (Table I).
Relationship between primary tumour and metastases
doubling times A strong correlation exists between
the labelling index (LI) in a breast tumour and its
metastases (Meyer et al., 1983). Moreover, in each
tumour type, the LI are strongly related to the
doubling times (Malaise et al., 1972). For
simplicity, we assume that there is a linear
relationship between the logarithmic values of the
doubling time of tumours and those of metastases.
In the case of the Gompertzian model, the
doubling time varies as a function of the volume.
One ml was chosen as the reference volume and the
relationship established between the doubling times
at one ml.
Calculation method
The calculation was performed with a Monte-Carlo
method (Hammersley & Handscomb, 1967).
For each pattern of growth (Vmvalue), the
estimation of the relationship between tumour and
metastases doubling times was carried out in the
following way: DT, VIT and VOT are taken at
random for 10,000 primary tumours from the log-
normal distributions with the relevant parameters
(Table 1). The mean and standard deviation of the
doubling times at 1 g (m(DT°) and SD(DT°)) are
calculated for the metastasising tumours (for which
VlT>VOT). The relationship between the DT° of a
tumour and of its metastases (DTM) is the
following:
DTM =aDTO+b,
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Thereafter, simulations are performed in order to
generate the metastases appearance curves. For
each primary tumour, DT, VIT and VOT are taken
at random from their relevant distribution. If VIT
is greater than VOT, there exists at least one
metastasis. The age (DI) of the metastasis when the
primary tumour reaches volume VIT (diagnosis) is
estimated as the duration of the primary tumour
growth between the size VOT up to the size VIT.
The duration (D2) of the metastasis growth up to
its clinical emergence is expressed as a number of
DTM. The delay between tumour diagnosis and
appearance ofthe metastasis is equal to D2-D1.
This process is iterated for 10,000 tumours and
the proportions of detectable metastases are
calculated as a function of the delay after treatment
and of the primary tumour volume at treatment.
The number of DTM corresponding to the
metastases growth duration is optimized by an
iteration procedure. This number has a strong
impact on the proportion of metastases at diagnosis
and is optimized in order to fit this proportion in
the total population.
The cumulated proportion of metastases at long
term as a function of the tumour volume depends
only on the distribution of the threshold volume
(VOT). This proportion is given by the chance that
VOT<VIT. The observed proportions are fitted by
the model.
The fit is assessed by a least square estimate
between the simulated metastasis appearance curves
and those calculated from the data.
Results
The proportion of metastases at diagnosis is fitted
for the entire population when the metastases
growth duration is taken equal to 16.5 DTM.
However, the model has to fit the metastases
appearance curves of the 3 classes of tumour sizes.
With the value of 16.5DTM, the simulated curves
corresponding to the classes of smaller tumour sizes
are above the confidence interval (Figure 2). For
these classes of tumours, the rate of metastasis
appearance is slower than predicted by the model.
This rate depends upon the metastases doubling
times and the discrepancy means that metastases
corresponding to small tumours grow more slowly
than metastases corresponding to large tumours. As
a first approximation, we may accept that
assumption and introduce a negative correlation
(RI) between tumour volume at diagnosis and
doubling time.
With this additional assumption, modifications of
the simulated curves corresponding to small and
large tumours were noticeable, even with a small
3
Time since treatment (y)
Figure 2 Confidence intervals at 5% level on the
observed metastases appearance curves (the area
between limits is shaded) and simulated curves. DT,
VIT and VOT are supposed independent of each other.
Each curve corresponds to one class of tumour clinical
diameter (D) (Curves no. 1: D<3.5cm; no. 2:
3.5<D<7.5cm; no. 3: D>7.5cm).
correlation. It was thus possible to improve the fit
for the curve corresponding to small tumours.
However, the fit for the curve corresponding to
intermediate size tumours was not significantly
improved.
An additional hypothesis has thus to be made in
order to adjust the 3 curves. We supposed that the
probability of metastasis is related to the tumour
doubling time (as shown by several clinical data)
(Tubiana et al., 1981, 1984; Gentilli et al., 1981;
Meyer et al., 1983). In other words, there exists a
correlation (R2) between tumour doubling time
(DT) and the threshold volume (VOT) (thus, VIT
was taken at random, then DT conditionally to
VIT, then VOT conditionally to DT). In these
conditions, VIT and VOT are indirectly correlated
and the threshold volume (VOT) distribution
parameters have to be recalculated (see Appendix).
The search for the couple RI and R2 giving the
best fit was performed through a systematic grid
search. Several hundred sets of R1, R2 values were
tried in this process. For each set, the metastases
growth duration was optimized.
The best fit (Figure 3) is obtained when
R1= -0.3 and R2=0.3. With these correlations,
the mean ratio between tumour and metastases
doubling time is found equal to 2.2 (metastases
grow 2.2 times faster than primary tumours). The
metastases growth duration is found equal to
18DTM, for all classes of tumour size.
The proportions of patients for whom the
metastases are aged less than 3, 6 or 12 months
(DI <3, 6 or 12 months) at the time of initial
diagnosis are found approximately equal to 0.07,
0.15 and 0.30, respectively.A MODEL OF THE NATURAL HISTORY OF BREAST CANCER 519
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Figure 3 Confidence intervals at 5% level on the
observed metastases appearance curves (the area
between limits is shaded) and simulated curves. The
correlation between doubling time and volume at
diagnosis (RI) is fixed to -0.3; the correlation between
doubling time and threshold volume (R2) to 0.3. Each
curve corresponds to one class of tumour clinical
diameter (D) (Curves no. 1: D .3.5cm; no. 2:
3.5<D<7.5cm; no. 3: D>7.5cm).
Concerning Gompertzian growth, a fit of the
proportion of metastases was possible for the entire
population, whatever the Vm value used. The
metastasis growth duration ranged from 16.5 to
18DTM. The ages of the metastases at tumour
diagnosis were similar to those obtained with
exponential growth. However, it was found
impossible to fit satisfactorily the proportions of
metastases at diagnosis as a function of the primary
tumour volume (Table II) with any value of RI and
R2.
Discussion
Consequences ofthe adjustment conditions
The occult history of metastases appears much
shorter than calculated with previous models. This
history is found equal to about 18DTM (on
average slightly less than 4 years).
Results concerning metastatic age at the time of
primary tumour diagnosis are consistent with data
of screening programs which have been shown to
reduce patient mortality by -30% (Shapiro et al.,
1982). According to the present model, this
reduction is that which would be obtained by
treating each patient 12 months earlier. The
estimates of the mean 'lead time' gained by
screening lie between 0.4 and 2.4 years, according
to a review by Walter & Day (1983). This
consistency supports the validity of the model and
encourages us to undertake similar calculations on
other types of tumours. No such concordance was
obtained with previous models, e.g., Igot & Legal
(1968) predicted a reduction in metastases incidence
of <5% when all tumours are treated when they
reach 1 g.
Table II Percentages (observed and simulated) of patients with metastases at diagnosis according
to different growth patterns
Simulated
D: Tumour Gompertzian
diameter
(cm) a Observed Vm =104ml Vm =105 ml Vm=10J' ml Exponential
All tumours p= 11.5 11.5 11.7 11.9 11.4
n= 2,648 10,000 10,000 10,000 10,000
s NS NS NS NS
D. 3.5 p= 3.6 0.4 0.8 0.9 2.4
n= 813 3,070 3,070 3,070 3,070
s *** *** *** NS
3.5<D<7.5 p= 11.7 8.4 9.6 10.4 11.4
n = 1,487 5,620 5,620 5,620 5,620
s *** * NS NS
D>7.5 p= 29.0 50.0 46.9 44.0 33.0
n= 348 1,310 1,310 1,310 1,310
s *** *** *** NS
ap =percentage of patients with metastases at diagnosis; n=number of patients in the class; s
=significance of the Chi square comparing the number of simulated to observed primary metastases
(NS non significant difference; * significant difference at 5% level; ** significant difference at 1%
level; *** significant difference at 0.1% level).520 S. KOSCIELNY et al.
Primary tumour growth pattern
The exponential is the simplest tumour growth
model. However, with almost all animal systems it
does not agree with experimental observations, and
growth curves are usually better described with a
Gompertzian function (Steel, 1977).
Human tumour growth cannot be studied as
extensively as in animals. It is therefore tempting to
extrapolate the results obtained with animals to
humans, and to consider that human tumour
growth is also Gompertzian.
With simulations performed under the
Gompertzian growth assumption, a fit of the
metastases appearance curve was possible for the
entire population of tumours. The metastases
growth duration and the ages of the metastases
were about the same as with the exponential model.
However, it was impossible to adjust the proportion
of metastases at diagnosis simultaneously in the 3
classes of tumour volume (Table II). The discrepan-
cies between the simulated and observed proportions
were highly significant with small values of Vm,
which are the most likely. These discrepancies were
reduced when Vm was increased.
Metastases growth duration (D2) is a constant
number of DTM. This number is independent of
the growth pattern. The growth pattern affects the
age of the metastasis at tumour diagnosis (Dl). Our
result indicates that the distribution of Dl cannot
be correctly estimated as a function of the primary
tumour volume at diagnosis with the Gompertzian
growth pattern. DI depends upon the volumes VOT
and VIT and on the growth pattern. Whatever the
supposed growth pattern, the proportions of
metastases at long term are correctly fitted as a
function of VIT. This means that the distribution
of VOT is correctly estimated conditionally to VIT.
Thus, the only explanation for the discrepancy is
that the primary tumour growth pattern is not
Gompertzian over the range of usual tumour sizes.
Implications concerning the metastases growth
pattern
The main result of our model is that the metastases
growth duration corresponds to - 18 DTM. Such a
duration is not compatible with the current concept
of an exponential growth starting from one single
cell (which leads to a duration of 30 DTM).
Little is known about metastases growth,
available data are sparse, even concerning doubling
times (Table I). Therefore, every growth scenario
compatible with a 18DTM growth duration should
be envisaged.
We can consider that metastases growth is
Gompertzian and is initiated by one single cell. In
this case, the maximum asymptotic volume (Vm)
has to be as large as 1066ml. However, as stated
above, a fit with the incidence of metastases
detected at tumour diagnosis requires an exponen-
tial growth pattern for the primary tumour between
VIT and VOT and it is difficult to accept a different
growth pattern for primary tumours and
metastases.
On the other hand, if we consider that metastases
growth is exponential, a 18DTM growth duration
implies an initial metastasis volume (VOM) of
-3,000 cells. This volume may be interpreted as
follows:
(i) Metastatic colonization occurs not by single
tumour cell but by multicell aggregates as found by
Slemmer (1979) for a murine mammary carcinoma.
The concept that initiation of tumour growth in
vivo should require the participation of several cells
has been proposed recently by Alexander (1985).
Nevertheless, 3,000 cells occupy a spheric volume of
about 200pm in diameter (i.e. twenty times the
diameter of an individual cell), and their migration
in bulk seems improbable.
(ii) Metastases containing <3,000 cells at the
time of the primary tumour treatment remain
undetectable. This may signify that one single cell is
sufficient to originate the process of metastasis, but
that after destruction of the primary tumour, only
those metastases which contain >3,000 cells
continue to proliferate. In this case, removal of the
primary tumour might be considered as a type of
immunotherapy, as stated by Morton & Wells
(1981)
The validity of these two interpretations is
questionable.
(iii) Another possibility is that during the very
first steps of its history, the metastasis grows much
faster than when it is detected. In this hypothesis,
metastases growth is characterized by a period of
very rapid proliferation followed by an exponential
phase. Such a situation has been observed with a
transplanted murine melanoma (Steel, 1977,
Figure 1.11).
Some considerations support this hypothesis.
Tumours contain stem cells and non-stem cells
(transient cells, end cells). Only stem cells are
capable of an unlimited proliferation. In human
tumours the proportion of stem cells is small.
However, this proportion, estimated a long time
after tumour initiation may not reflect the situation
at the start. The metastasis may originate from one
stem cell with a period of rapid proliferation
corresponding to a filling of the non-stem cell
compartment (See MacKillok et al., 1983).
In human tumours, the proportion of stem cells
has been estimated as about 1/1,000 by Trott et al.
(1984). The similarity between the total number of
cells per stem cell (1,000) and the estimated value ofA MODEL OF THE NATURAL HISTORY OF BREAST CANCER 521
VOM (3,000) is noteworthy. A possible relation
between the apparent growth duration and the
proportion of stem cells has to be investigated.
In summary, the concept of 18 DTM and
exponential growth of metastases does not
necessarily mean that the initial metastases volume
is 3,000 cells. It is more an operational concept
because the back extrapolation over the entire
history of the metastasis is not valid and may
overestimate the initial metastasis volume.
Previous model
Slack et al. (1969) have proposed a model to
describe the natural history of breast cancer, with
the aim of fitting the proportions of metastases
which appeared 18 and 60 months after the
treatment of the primary tumour. They assumed
that tumour growth is exponential, starting from
one cell, and that tumours and metastases have
identical growth rates. Using their model, it was
necessary to postulate the existence of two
categories of breast cancers differing by their
doubling times (1.4, and 0.7 months), as well as by
the relative risks of metastatic dissemination (1:1.9)
and nodal involvement (1:8).
Concerning the characteristics of these
populations, the estimated tumour and metastases
doubling times are much shorter than the measured
values (Tubiana et al., 1975; and Table I). More-
over, it has been found that the distribution of the
doubling time is lognormal (Charbit et al., 1971;
Steel, 1977) and not bimodal, as it would be if
there were two groups of breast cancers.
Finally, with our model, it is not necessary to
postulate the existence of two populations of breast
cancers. Concerning this point, the result of Slack
et al. (1969) seems artefactual. This is probably due
to the fact that Slack et al. (1969) did not account
for variability in the parameters.
Data concermnng scar recurrences can be
examined on the light of our results. Philippe & Le
Gal (1968) and later Pearlman (1976) estimated the
doubling times of recurrences assuming an
exponential growth starting from one single cell.
They divided the delay between surgery and
recurrence by 30 (number of DT from one cell up
to 1 g). The median recurrence doubling time was
estimated as 21 days by Pearlman, and 29 days by
Philippe & Le Gal. The present model suggests that
the delay should have been divided by 18, which
leads to median recurrence doubling times of 35
and 49 days, values which are close to the estimated
pulmonary metastasis doubling time.
Consistency of our data
The data used in this model, were obtained from
various sources. In order to assess the possible
effect of biased data on our results, we have
performed simulations with modified distribution
parameters. As shown in Table III, the adjustment
conditions were only slightly modified. In all cases,
it must be noted that RI is negative, and R2
positive. The estimated metastases growth duration
is always approximately the same.
Results concerning the age of the metastases are
not modified.
Relations between the parameters
A determinist relationship has been assumed
between metastasing tumours and metastases
doubling times. The results are only slightly
Table Ill Adjustment conditions as a function of the parameters of the various distributions. The
parameters given in the first line are those of the literature. In the subsequent lines the modified
parameter is indicated by (+)
Parameters Results
M DT M DTM Duration
(months) SD DT (months) SD DTM RI R2 DTM (months) r
7 0.72 2.5 0.85 -0.3 0.3 18.3 (45.9) 2.2
5.5(+) 0.72 2.5 0.85 -0.4 0.5 18.3 (45.9) 1.7
9 (+) 0.72 2.5 0.85 -0.2 0.2 21.6 (54.0) 3.2
7 0.72 2.0(+) 0.85 -0.3 0.3 23.3 (46.6) 2.9
7 0.72 4.0(+) 0.85 -0.3 0.3 11.6 (46.5) 1.5
7 0.60(+) 2.5 0.85 -0.2 0.2 18.3 (45.9) 2.5
7 0.85(+) 2.5 0.85 -0.4 0.4 19.1 (47.8) 2.1
7 0.72 2.5 0.70(+) -0.4 0.4 19.9 (49.8) 2.2
7 0.72 2.5 1.00(+) -0.2 0.2 18.3 (45.9) 2.4
r is the ratio between the doubling times of metastasising tumours and of metastases; M is the
median value; SD is the standard deviation of the logarithms of the values; Duration is the metastases
growth duration (DTM: number of DTM; months: median duration in months).522 S. KOSCIELNY et al.
modified if a correlation of 0.7 (instead of 1) is set
between these doubling times (RI, R2, the
estimated metastases growth duration and the ages
of the metastases are not modified, but the fit of
the big tumours metastases appearance curves is
worse).
The correlation between tumour volume at
diagnosis and doubling time (RI) is found equal to
-0.3. With such a small value, it is not surprising
that most authors, particularly Fournier et al.
(1980) who studied 147 tumours, did not find
significant correlations between volume and
doubling time. However, Kusama et al. (1972)
reported that large tumours have, on the average, a
shorter doubling time than small tumours.
Moreover labelling indices (LI) are slightly higher
in large tumours, but the difference is small and not
significant (Tubiana et al. 1981; Meyer et al., 1983).
On the other hand, the -0.3 value is the same as
that deduced by Atkinson et al. (1983) from data
on primary tumour size at diagnosis.
The positive correlation (R2) between tumour
doubling time and threshold volume is consistent
with observations concerning the prognostic value
of the LI: rapidly proliferating tumours disseminate
more often than less proliferating ones (Tubiana et
al., 1981, 1984; Gentilli et al., 1981; Meyer et al.
1983).
The ratio between the median doubling times of
the metastasising tumours and of the metastases is
2.2. The discrepancy between this value and the
crude ratio between the median doubling times of
tumours and metastases (Table I) is explained by
the shorter doubling times of metastasising
tumours.
Conclusion
Previous models have not taken into account the
relationship between tumour volume at treatment
and metastatic dissemination probability; neither
did they consider the variability of doubling times
of tumours and metastases, nor the fact that the
growth rates of tumours and metastases are, on the
average, different.
The metastases growth duration, in our model, is
not fixed a priori, but estimated. This duration is
found equal to 18DTM, that is about half the
duration estimated with an exponential growth
starting from one single cell.
The occult history of metastases (on the average
3.8 years) is found shorter than usually assumed (17
years if the metastases growth is supposed the same
as the primary tumour one). A 30% reduction in
metastases incidence is predicted if the primary
tumours are treated 12 months earlier, which is in
accordance with the results of screening programs.
This concordance encourages us to explore further
the possible uses of such models for other tumour
sites.
We wish to express our gratitude to Drs. N. Blackett and
J.Y. Mary for their careful reading of the text and their
helpful comments and suggestions.
Appendix
Correlation between VIT and VOT
The partial correlation between VlT and VOT is
considered equal to zero when DT is fixed
(notation:RVITVOT/DT=0).
This restriction can be written:
K-R1 R2
RVlTVOT/DT=O= -
(1 -R12)(1-R22)
(1)
where K is the correlation between VIT and VOT, RI the
correlation between VIT and DT and R2 the correlation
between VOT and DT.
This restriction implies that
K=R1R2.
The value of K is independent of the parameters of the
threshold volume distribution.
Distribution ofthe threshold volume
In a previous paper (Koscielny et al., 1984), independence
was assumed between the volume at diagnosis VIT and
VOT. Under this assumption, the threshold volume (VOT)
distribution was estimated from the relationship between
the cumulated proportion (p) of metastases at long term
and the logarithm of the tumour volume (VIT) at
treatment. This relation, interpreted in terms of quantal
response (Finney et al., 1964) can be written:
Y =probit(p) -5 = IT -( eVOT)
(aeVOT)
Y=aVl+b;
(2)
(3)
the coefficients a and b are respectively equal to 1/oeVOT
and -peVOT/ceVOT where jeVOT and aeVOT are the
mean and the SD of the distribution of the logarithm of
the threshold volume estimated from the data.
When K (correlation between VIT and VOT) is not nil,
the distribution of VOT must be recalculated conditionally
to the value of K.
pVOT and aVOT are the mean and the SD of VOT
distribution, conditionally to the value of K.
uVOT/V1T=MVOT+KaVOT/aV1T(VlT-pV1T), (4)
aVOT/V1T=aVOT /1-K . (5)A MODEL OF THE NATURAL HISTORY OF BREAST CANCER 523
A relationship similar to (2) is
V1T-yVOT/V1T Y= . ~~~~~~~~~(6) cVOT/VIT
The parameters a and b now refer to:
1-(KaVOT/aV1T)
a=- .(7)
VOT T -K2
- VOT-KVOT/aVlTyV1T (8)
VOT T -K2
where
aeVOTaV1T
arVOT= , (9)
VlT 1-K2+KaeVOT
VOT= eVOTaV1T / 1K2+KaeVOTpV1T (10)
VITV -K2+KaeVOT
Quantification ofthe growth
With the Gompertzian growth function, the relation
between volume and time (Gatton et al., 1978) is:
Ln(Vt)=a-bexp(-ct), (11)
where
a=Ln(Vm); (12)
Vm represents the maximum asymptotic volume
(volume that would be reached after an infinite period of
growth), and
b=Ln(Vm/Vi). (13)
Vi is the initial volume (at time 0).
The doubling time at time t is equal to:
DTt=Ln(2)/bcexp(-ct). (14)
From (11) and (12),
bexp(-ct) =Ln(Vm/Vt). (15)
From (13) and (15),
ct=Ln(Ln(Vm/Vi)/Ln(Vm/Vt)). (16)
From (14) and (15),
cDTt=Ln(2)/Ln(Vm/Vt). (17)
The ratio (16)/(17) gives the value of t as a function of
DTt:
t=DTtLn{Ln(Vm/Vi)/Ln(Vm/Vt)} Ln(Vm/Vt)/Ln(2).
(18)
Concerning doubling times, we can write
cDT° =Ln(2)/Ln(Vm/V°). (19)
where DT° is the doubling time when the volume is VW.
From (17) and (19),
DT° =DTtLn(Vm/Vt)/Ln(Vm/V°). (20)
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